No results for ‘’
Brawn Biotech Ltd
₹21.60
(0%)
Mon, 25 May 2026, 11:40 am
Health Technology
Pharmaceuticals: Major
24.5KBrawn Biotech Enterprise Value (EV)
| Particulars | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 12.23 | 9.38 | 14.18 | 12.07 | 4.17 | 11.72 | 10.16 | 14.51 | 14.85 | 12.60 | 8.36 | 9.46 | 0 | 0 | 0 | 0 | 0 |
| Price to book ratio | 1.30 | 1.15 | 0.73 | 0.50 | 0.42 | 0.29 | 0.61 | 2.50 | 2.99 | 2.12 | 1.29 | 0.60 | 0.75 | 0.72 | 0.79 | 1.18 | 1.45 |
| Price to sales ratio | 1.14 | 4.75 | 0.19 | 0.14 | 0.08 | 0.04 | 0.08 | 0.30 | 0.35 | 0.29 | 0.17 | 0.11 | 0.19 | 0.60 | 0.22 | 0.37 | 0.36 |
| Price to cash flow ratio | 302.85 | 201.89 | 0 | 25.78 | 0 | 29.40 | 23.80 | 43.45 | 15.88 | 0 | 74.56 | 0 | 0 | 41.53 | 16.03 | 0 | 111.39 |
| Enterprise value | 45.06M | 45.03M | 31.64M | 19.27M | 17.38M | 11.84M | 28.73M | 137.52M | 186.73M | 157.46M | 106.01M | 51.96M | 62.34M | 49.81M | 45.27M | 56.03M | 46.76M |
| Enterprise value to EBITDA ratio | 15.78 | 0 | 7.87 | 0 | 0 | 0 | 0 | 62.21 | 14.99 | 8.03 | 9.13 | 7.09 | 0 | 0 | 0 | 0 | 0 |
| Debt to equity ratio | 0 | 0 | 0.07 | 0.01 | 0 | 0 | 0.02 | 0.02 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Return on equity % | 0 | 13 | 5.27 | 4.20 | 10.43 | 2.58 | 6.22 | 18.21 | 22.44 | 18.34 | 16.38 | 6.60 | -6.10 | -20.53 | -12.83 | -21.93 | -41.30 |
Brawn Biotech Ltd Enterprise Value
The Brawn Biotech Ltd Enterprise Value is a key financial metric used by investors to evaluate Brawn Biotech Ltd's valuation, profitability, and overall financial performance. Tracking the Brawn Biotech Ltd Enterprise Value helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.
Brawn Biotech Ltd (NSE: , BSE: 530207) is currently trading at ₹21.60, with a market capitalization of ₹64.81M. As a leading company in the Health technology sector and Pharmaceuticals: major industry, monitoring the Brawn Biotech Ltd Enterprise Value is essential for fundamental analysis.
Brawn Biotech Ltd Enterprise Value Current Value
The current Brawn Biotech Ltd Enterprise Value stands at 46.76M.
The Brawn Biotech Ltd Enterprise Value has declined compared to earlier levels, suggesting improved fundamentals or more attractive valuation.
Brawn Biotech Ltd Enterprise Value Historical Trend
The Brawn Biotech Ltd Enterprise Value has shown the following historical trend:
- 2024: 46.76M
- 2023: 56.03M
- 2022: 45.27M
- 2021: 49.81M
- 2020: 62.34M
The decline in Brawn Biotech Ltd Enterprise Value indicates improving financial efficiency or better earnings growth.
What Brawn Biotech Ltd Enterprise Value Indicates for Investors
The Brawn Biotech Ltd Enterprise Value plays a crucial role in understanding the company's financial health and valuation.
This ratio is an important metric used in fundamental analysis of Brawn Biotech Ltd.
Brawn Biotech Ltd Enterprise Value Analysis Summary
The Brawn Biotech Ltd Enterprise Value remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Brawn Biotech Ltd Enterprise Value should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.
Regular tracking of Brawn Biotech Ltd Enterprise Value helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.